SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
X	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* Mohler Kendall (Last) (First) (Middle) 2401 4TH AVE., SUITE 1050 (Street) SEATTLE WA 98121 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol Trubion Pharmaceuticals, Inc [ TRBN ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) SVP & Chief Scientific Officer
	3. Date of Earliest Transaction (Month/Day/Year) 10/28/2010
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/28/2010		D		140,206	D	(1)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$0.31	10/28/2010		D			34,882	(2)	12/20/2012	Common Stock	34,882	$0.00	0	D
Employee Stock Option (right to buy)	$0.31	10/28/2010		D			39,730	(3)	12/16/2014	Common Stock	39,730	$0.00	0	D
Employee Stock Option (right to buy)	$0.31	10/28/2010		D			13,243	(4)	02/03/2015	Common Stock	13,243	$0.00	0	D
Employee Stock Option (right to buy)	$0.31	10/28/2010		D			770	(5)	04/28/2015	Common Stock	770	$0.00	0	D
Employee Stock Option (right to buy)	$2.69	10/28/2010		D			19,865	(6)	11/30/2015	Common Stock	19,865	$0.00	0	D
Employee Stock Option (right to buy)	$6.52	10/28/2010		D			7,335	(7)	01/25/2016	Common Stock	7,335	$0.00	0	D
Employee Stock Option (right to buy)	$6.52	10/28/2010		D			23,919	(8)	03/08/2016	Common Stock	23,919	$0.00	0	D
Employee Stock Option (right to buy)	$6.52	10/28/2010		D			19,865	(9)	03/08/2016	Common Stock	19,865	$0.00	0	D
Employee Stock Option (right to buy)	$8.98	10/28/2010		D			52,000	(10)	01/31/2018	Common Stock	52,000	$0.00	0	D
Employee Stock Option (right to buy)	$1.33	10/28/2010		D			50,000	(11)	01/30/2019	Common Stock	50,000	$0.00	0	D
Employee Stock Option (right to buy)	$1.33	10/28/2010		D			27,500	(12)	01/30/2019	Common Stock	27,500	$0.00	0	D
Employee Stock Option (right to buy)	$3.82	10/28/2010		D			45,000	(13)	01/29/2020	Common Stock	45,000	$0.00	0	D

Explanation of Responses:

1. Disposed of pursuant to merger agreement among the issuer and Emergent BioSolutions Inc., and certain of its affiliates, in exchange for (a) an aggregate of $191,381.19 cash, (b) 23,007 shares of Emergent common stock having a market value of $18.26 per share on the effective date of the merger and (c)140,206 contingent value rights, which represent the right to receive possible additional cash payments.

2. This option, which was 100% vested on November 15, 2006, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates in exchange for (a) a cash payment of $147,760.15, representing the difference between the exercise price and the initial merger consideration of $4.55 per share, and (b) 34,882 contingent value rights, which represents the right to receive possible additional future cash payments.

3. This option, which was 100% vested on July 13, 2008, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates in exchange for (a) a cash payment of $168,296.28, representing the difference between the exercise price and the initial merger consideration of $4.55 per share, and (b) 39.730 contingent value rights, which represents the right to receive possible additional future cash payments.

4. This option, which was 100% vested on July 13, 2008, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates in exchange for (a) a cash payment of $56,103.31, representing the difference between the exercise price and the initial merger consideration of $4.55 per share, and (b) 13,243 contingent value rights, which represents the right to receive possible additional future cash payments.

5. This option, which was 100% vested on January 1, 2006, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates in exchange for (a) a cash payment of $3,261.72, representing the difference between the exercise price and the initial merger consideration of $4.55 per share, and (b) 770 contingent value rights, which represents the right to receive possible additional future cash payments.

6. This option, which was 100% vested on July 13, 2008, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates in exchange for (a) a cash payment of $36,812.95, representing the difference between the exercise price and the initial merger consideration of $4.55 per share, and (b) 19,865 contingent value rights, which represents the right to receive possible additional future cash payments.

7. This option, which was 100% vested on January 1, 2007, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates, without any consideration being received.

8. This option, which was 100% vested on January 1, 2010, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates, without any consideration being received.

9. This option, which was 100% vested on July 13, 2008, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates, without any consideration being received.

10. This option, which provided for vesting at the rate of 1/48th on February 1, 2008, and 1/48th monthly thereafter, such that all of the shares would be fully vested as of January 1, 2012, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates, without any consideration being received.

11. This option, which provided for vesting at the rate of 1/48th on February 1, 2009, and then 1/48th monthly thereafter, such that all of the shares would be fully vested as of January 1, 2013, was vested in its entirety and then cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates in exchange for (a) a cash payment of $161,000, representing the difference between the exercise price and the initial merger consideration of $4.55 per share, and (b) 50,000 contingent value rights, which represents the right to receive possible additional future cash payments.

12. This option, which provided for vesting at the rate of 1/36th on August 27, 2009, and then 1/36th monthly thereafter, such that all of the shares would be fully vested as of July 27, 2012, was vested in its entirety and then cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates in exchange for (a) a cash payment of $88,550, representing the difference between the exercise price and the initial merger consideration of $4.55 per share, and (b)27,500 contingent value rights, which represents the right to receive possible additional future cash payments.

13. This option, which provided for vesting at the rate of 1/48th on February 1, 2010, and then 1/48th monthly thereafter, such that all of the shares would be fully vested as of January 1, 2014, was vested in its entirety and then cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates in exchange for (a) a cash payment of $32,850, representing the difference between the exercise price and the initial merger consideration of $4.55 per share, and (b) 45,000 contingent value rights, which represents the right to receive possible additional future cash payments.

Remarks:

	/s/ Kathleen M. Deeley, Attorney-in-fact for Kendall Mohler	10/28/2010
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.